Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-part, Phase I/II, Randomized, Observer-blinded, Controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines Administered at 0 and 28 Days as Compared to Comirnaty, and of a Booster Dose of ZR202a-CoV Vaccine in Healthy Adults.

Next Previous
X
Search
Trial Profile

A Two-part, Phase I/II, Randomized, Observer-blinded, Controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines Administered at 0 and 28 Days as Compared to Comirnaty, and of a Booster Dose of ZR202a-CoV Vaccine in Healthy Adults.

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 202-CoV (Primary) ; Tozinameran
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Sponsors Shanghai Zerun Biotechnology Co

    • Most Recent Events

    • 01 Nov 2024 Results assessing safety and immunogenicity , published in the International Journal of Infectious Diseases
    • 18 Apr 2023 Planned End Date changed from 1 Dec 2023 to 1 Aug 2023.
    • 18 Apr 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top